Presentatie - vzw farmaka asbl

More documents

Recommendations

Info

- CABG vs enkel medicatie - • ↓ Mortaliteit na 5-10 j • ↑ Mortaliteit en CV events tot 1 jaar na CABG www.<strong>farmaka</strong>.be Project Farmaka
Stents 30.Brophy. Evidence for use of coronary stents. A hierarchical Bayesian meta-analysis. Ann Intern Med 2003;138:777-86 Design N/n Population Sd Interventions Outcomes Results MA N=29, n=9918 -Stable or unstable angina -6 to 16 months -PTCA with stent -PTCA without stent Mortality -1.2% (zonder stent) vs 0.8% -OR= 0.69 (95%CI 0.43 to 1.05) Mortality OR MI -ARD= - 0.50% in favour of stent -OR= 0.90 (95%CI 0.72 to 1.11) CABG OR= 1.01 (95%CI 0.79 to 1.31) Angiographic restenosis -40% (zonder stent) vs 27% (ongecorrigeerde cijfers) -ARD= 14.5% in favour of stent -OR= 0.52 (95%CI 0.37 to 0.69) Recurrent PTCA -ARD= 6.8% in favour of stent -OR= 0.59 (95%CI 0.50 to 0.68) ARD= absolute risk difference Hill. Drug-eluting stents: a systematic review and economic evaluation. HTA 2007 Design N/n Population Sd Interventions Outcomes Results MA N=17, -Coronary -Up to 3 -Bare metal stent Mortality No differences n>7000 artery disease years -Drug-eluting stent MI No differences (in most studies Revascularisation Typically 5% (DES) vs 10 to 25% exclusion of (BMS) at 1 year recent MI) SS difference in favour of DES Restenosis (> 50% SS difference in favour of DES narrowing of lumen after stenting) www.<strong>farmaka</strong>.be Project Farmaka
Page 1 and 2:
Projekt Farmaka vzw Centrum voor on
Page 3 and 4:
Hoe? 1. Van een klinisch probleem n
Page 5 and 6:
Aanpak van stabiele angor www.farma
Page 7 and 8:
Definitie en epidemiologie www.farm
Page 9 and 10:
Natuurlijk verloop www.farmaka.be P
Page 11 and 12: Doelstelling van de behandeling www
Page 13 and 14: Acute behandeling www.farmaka.be Pr
Page 15 and 16: Anti-anginosa (onderhoudsbehandelin
Page 17 and 18: ANTIANGINOSA (niet in België) - we
Page 19 and 20: β-blokkers Niet-selectieve β-blok
Page 21: NITRATEN Sublinguaal Posologie Isos
Page 24 and 25: β-blokkers 17.Pepine. The atenolol
Page 26 and 27: β-blokkers Preserved ventricular f
Page 28 and 29: β-blokkers Helfand 2007 www.farmak
Page 30 and 31: - β-blokkers - • Mortaliteit en
Page 32 and 33: Calcium-antagonisten Gami P. Second
Page 34 and 35: • Werkzaam op angor - Calciumanta
Page 36 and 37: Nitraten 25.Heidenreich. JAMA 1999;
Page 38 and 39: - Molsidomine - • Werkzaamheid op
Page 40 and 41: - Trimetazidine, ranolazine, nicora
Page 42 and 43: - Combinaties en werkzaamheid angor
Page 44 and 45: Anti-anginosa - ongewenste effecten
Page 50 and 51: Invasieve behandeling www.farmaka.b
Page 52 and 53: - Aanvullende medicatie bij PCI -
Page 54 and 55: www.farmaka.be Project Farmaka
Page 56 and 57: - Terminologie invasieve ingrepen -
Page 58 and 59: PTCA vs enkel medicatie 53.Borzak.
Page 60 and 61: - PTCA vs enkel medicatie - • Bej
Page 64: -Stents - Bedoeling stents en DES:
Page 67 and 68: - CABG vs PTCA - • CABG: meer CVA
Page 69 and 70: Onderhoudsbehandeling Globale CV pr
Page 71 and 72: Rookstop Gami P. Secondary preventi
Page 73 and 74: Mediterraan dieet 1.Gami P. Seconda
Page 75 and 76: Oefentherapie 77. Gami P. Secondary
Page 77 and 78: - Oefentherapie - • Vs “usual t
Page 79 and 80: - Stressmanagement - • Mogelijk
Page 81 and 82: - β-blokkers - Zie hoger www.farma
Page 83 and 84: Anti-aggregantia - ASA Gami P. Seco
Page 85 and 86: Consensusvergadering angor 2006. Di
Page 87 and 88: Anti-aggregantia - Ticlopidine en
Page 89 and 90: ACE-inhibitoren • Bij hoogrisicop
Page 91 and 92: - Sartanen - • Ramipril vs telmis
Page 93 and 94: -Statines - • ↓ mortaliteit en
Page 95 and 96: - Kernboodschappen - Patiënt met s
Page 97 and 98: - Symptomatische behandeling - •
show all

Presentatie - vzw farmaka asbl

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?